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Abstract
Activating K-RAS mutations occur at a frequency of 90% in pancreatic cancer, and to date no therapies exist targeting this
oncogene. K-RAS signals via downstream effector pathways such as the MAPK and the PI3K signaling pathways, and much
effort has been focused on developing drugs targeting components of these pathways. To better understand the
requirements for K-RAS and its downstream signaling pathways MAPK and PI3K in pancreatic tumor maintenance, we
established an inducible K-RAS knock down system that allowed us to ablate K-RAS in established tumors. Knock down of K-
RAS resulted in impaired tumor growth in all pancreatic xenograft models tested, demonstrating that K-RAS expression is
indeed required for tumor maintenance of K-RAS mutant pancreatic tumors. We further examined signaling downstream of
K-RAS, and detected a robust reduction of pERK levels upon K-RAS knock down. In contrast, no effect on pAKT levels could
be observed due to almost undetectable basal expression levels. To investigate the requirement of the MAPK and the PI3K
pathways on tumor maintenance, three selected pancreatic xenograft models were tested for their response to MEK or PI3K
inhibition. Tumors of all three models regressed upon MEK inhibition, but showed less pronounced response to PI3K
inhibition. The effect of MEK inhibition on pancreatic xenografts could be enhanced further by combined application of
a PI3K inhibitor. These data provide further rationale for testing combinations of MEK and PI3K inhibitors in clinical trials
comprising a patient population with pancreatic cancer harboring mutations in K-RAS.
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Introduction
The small GTPase K-RAS is frequently mutated in human
cancers, with mutations occurring in 90% of non neuro-endocrine
pancreatic tumors [1]. The presence of these mutations locks the
protein in a constitutively activated form, which in turn results in
enhanced stimulation of proliferative pathways, thus conferring
a growth advantage on the cancer cell [2]. A number of genetic
studies have shown that such activating K-RAS mutations are
necessary for the onset of pancreatic cancer [3–5]. An inducible
pancreas-specific expression system was used recently to show that
K-RASG12D expression is also required for tumor maintenance
[6]. This renders K-RAS a highly validated target for which
specific inhibitors are expected to lead to antitumor efficacy.
Unfortunately, all attempts to develop such molecular entities have
failed so far, placing this target in the so-called difficult-to-drug
target category [7–8]. Alternative strategies rely on inhibition of
key downstream effectors, an approach reminiscent to the hunt for
synthetic lethal interactors [9].
K-RAS signals via a number of downstream effectors, amongst
others RAF kinase, PI3 kinase (PI3K), exchange factors for the
small GTPases RAL and RAC as well as phospholipase C e [10].
The RAF-MEK-ERK (MAPK) and the PI3K pathways are well
described mediators of RAS induced transformation and tumor-
igenesis [11–12]. The in vivo significance of PI3K in K-RAS
mediated tumorigenesis in the lung has been demonstrated using
mice genetically engineered to carry a PI3K mutation deficient in
RAS binding [13]. However, the role of either pathway in tumor
maintenance is less clear. In the lung, it appears that MAPK
signaling plays a more important role in tumor maintenance than
PI3K signaling, since treatment of established K-RAS mutant lung
tumors was more effective using MEK inhibitors than using PI3K
inhibitors [14–15]. In pancreatic tumors, there are hints that the
PI3K as well as the MAPK pathway might be involved in tumor
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maintenance [16–19]. However, the function of these pathways in
tumor maintenance of the pancreatic lineage still needs further
elucidation, since a better understanding of the contribution of K-
RAS effectors to tumor maintenance might help to identify
therapies alternative to targeting K-RAS itself.
There is a trend towards treatment with combinations of
inhibitors rather than with single inhibitors. The importance of
tumor-host interactions is well known in the case of pancreatic
cancer, with hedgehog as well as PI3K signaling playing an
important role in regulating the tumor stroma [20–21]. Targeting
both tumor cells as well as the tumor stroma might therefore be
necessary to effectively treat such cancers. Furthermore, in K-RAS
mutant tumors in which K-RAS signals via multiple effector
pathways, inhibition of several of these pathways is likely to be
more effective than targeting just a single one. Finally, there are
feedback loops between the MAPK and the PI3K pathway, which
can result in activation of one pathway upon inhibition of the
other, and in this way confer resistance to single agent treatment
[15,22–23]. Combinations of MEK and PI3K inhibitors have
been tested in models of K-RAS mutant breast, lung and
colorectal cancer, and were shown to be superior to single agent
treatment [14–15,24–26]. It remains to be seen if such combina-
tion treatment can be successfully applied to K-RAS mutant
pancreatic models as well.
In this study, we set out to better understand the involvement of
K-RAS as well as of the MAPK and PI3K signaling pathways in
tumor maintenance of pancreatic cancer models in vivo. We
developed an inducible K-RAS knock down system which allowed
us to confirm requirement of pancreatic tumor maintenance on K-
RAS. Having shown K-RAS dependence of our model system, we
next tested involvement of the MEK or PI3K pathways in the
maintenance of K-RAS dependent tumors. Response to MEK or
PI3K inhibition was tested in three selected xenograft models, all
of which showed tumor regression upon MEK inhibitor treatment,
but not upon PI3K inhibitor treatment. Thus, all pancreatic
models tested were more dependent on MAPK than on PI3K
signaling. As PI3K plays important roles in regulating the tumor
stroma, combined inhibition of MEK and PI3K might prove
beneficial to single agent treatment despite minor effects of PI3K
inhibition on tumor growth. Indeed, combining MEK and PI3K
inhibitors led to superior effects compared to single agent
treatment.
Results
K-RAS is Required for Tumor Maintenance in vivo
Expression of mutant K-RAS is known to be required for tumor
maintenance in a genetically engineered mouse model of
pancreatic cancer [6]. To expand on this study, and to confirm
the relevance of the findings in human cancer models, we
established doxycycline-inducible K-RAS shRNA expression in
five K-RAS mutant human pancreatic cell lines (Capan-1, Panc
10.05, AsPC-1, L3.3 and PANC-1) (Table S1). Doxycycline
treatment led to effective K-RAS knock down upon K-RAS
specific sh236 and sh562 expression in all lines tested in vitro. In
contrast, no knock down was observed in the non-targeting
shRNA (shNT) control pools (Figure 1A). With the exception of
the L3.3 line, for which leaky expression of sh562 resulted in
increased doubling times, all five K-RAS mutant pancreatic
models showed impaired growth upon expression of either sh236
or sh562 when tested in proliferation assays (Figure 1B and Figure
S1). No effect on growth was observed when sh236 was expressed
in the K-RAS wild type lung line NCI-H1437, despite significant
reduction of K-RAS protein levels, demonstrating the specificity of
K-RAS knock down (Figure S2). Overall, these data confirm
previously published findings showing dependence of in vitro
proliferation on expression of mutant K-RAS in pancreatic cell
lines [27–29]. Next, we examined effects of K-RAS knockdown on
downstream signaling, and found a robust decrease of pERK
levels in the Capan-1, Panc 10.05 and L3.3 lines. With the
exception of the AsPC1 line, pAKT levels were found to be almost
unaffected upon K-RAS knockdown (Figure 1A).
We next tested K-RAS dependence in vivo by performing nude
mouse xenograft studies with four out of the five human K-RAS
mutant lines (Capan-1, Panc10.05, AsPC-1 and L3.3) described
above, as well as for the wild type K-RAS control line NCI-
H1437. The functionality of the K-RAS knock down system in
these models was first assessed by treating tumor-bearing mice
with doxycycline for 7 days. This resulted in a 60 to 80% reduction
of K-RAS transcript levels upon expression of shRNA236, in
contrast to the non-targeting shRNA control (Figure 2A). Hence,
this system is suitable for studying the role of K-RAS expression in
already established tumors. Long-term doxycycline treatment of
sh236 Capan1 tumor bearing mice resulted in significant
antitumor activity leading to tumor stasis. No antitumor activity
was observed in shNT Capan1 tumor bearing mice, showing that
inhibition of tumor growth is not caused by unspecific effects of
doxycycline treatment (Figure 2B). Similar studies were performed
with the Panc 10.05, AsPC-1 and L3.3 models, for which
doxycycline treatment resulted in tumor growth inhibition in all
three cases (Figure 2C). The effects were always statistically
significant when the tumor volumes across the entire study were
considered by calculating the area under the curve (AUC)
(Figure 2B/C and Table S2). Ablation of K-RAS expression in
the NCI-H1437 tumors, however, did not result in impaired
tumor growth, and thus shows K-RAS independence of this model
for tumor maintenance in vivo (Figure 2A and 2C). In conclusion,
we showed that mutant K-RAS is required for tumor maintenance
of the pancreatic lineage in an in vivo xenograft system using
human cancer cell lines.
K-RAS Signals via MAPK in vivo
Tumor-stroma interactions have been shown to play a critical
role in pancreatic cancer [6,20–21,30]. Hence, signaling events
specific to the tumor environment can not be captured in in vitro
systems. Our K-RAS dependent model system allows in vivo
investigation of downstream signaling pathways employed by
mutant K-RAS. pERK and pAKT levels were examined as
readout for MAPK and PI3K pathway activity respectively by
immunohistochemistry, as this has the advantage to allow
discrimination of tumor tissue from tumor stroma. Basal pERK
levels were readily detectable and were substantially decreased
after 7 days of K-RAS shRNA expression in all four models
(Capan-1, Panc 10.05, AsPC-1 and L3.3), whereas no changes
were observed when the non-targeting shRNA was expressed.
Hence, ERK is activated downstream of K-RAS in these tumor
models (Figure 3A).
In sharp contrast, basal pAKT levels were found to be very low
- almost undetectable - in all tumors tested. As positive control,
pAKT expression was also determined and shown to be detectable
in sections of the PI3K mutant, AKT-dependent breast cancer
T47D tumors. (Figure 3B) [31]. It has to be noted that the effect of
K-RAS knockdown on downstream phosphoprotein levels does
not completely correlate between in vivo and in vitro settings, with
pERK levels being affected strongly across all in vivo models
(Figure 1A).
To exclude the possibility that even such low levels of pAKT
could be sufficient to promote physiologically relevant signaling,
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Figure 1. K-RAS knock down impairs proliferation in pancreatic lines in vitro. (A) Indicated cell lines (NT: non-targeting shRNA; 236 and 562:
shRNAs targeting K-RAS) were either treated for 7 days with 200 ng/ml doxycycline (dox) or left untreated (no dox), followed by preparation of cell
lysates. Corresponding cell extracts were then analyzed for K-RAS, total AKT, pAKT (Ser473), total ERK or pERK (Thr202/Tyr204) levels by Western Blot.
(B) As in (A), except that cells were fixed on day 1 and day 7, followed by determination of relative cell number. Each cell line was tested in at least
two independent experiments, and untreated samples were set to 100% of growth. Statistically significant differences (p,0.05) are indicated (*).
Obtained p-values were as follows: Capan-1 shNT: p = 1, Capan-1 sh236: p = 0.002, Capan-1 sh562: p = 0.029; Panc 10.05 shNT: p = 0.33, Panc 10.05
sh236: p,0.001, Panc 10.05 sh562: p = 0.029; AsPc1 shNT: p = 0.33, AsPc1 sh236: p = 0.002, AsPc1 sh562: p = 0.029; L3.3 shNT: p = 0.187, L3.3 sh236:
p,0.001, L3.3 sh562: p = 0.333; PANC-1 shNT: p = 1, PANC-1 sh236: p,0.001, PANC-1 sh562: p = 0.002.
doi:10.1371/journal.pone.0044146.g001
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sensitivity to the AKT inhibitor MK2206 was tested in vitro [32].
As expected, the control line T47D was sensitive to MK2206,
reflected by nanomolar GI50 values (GI50 = 140 nM). In contrast,
no significant effect of AKT inhibition was seen on the pancreatic
cell lines in vitro, with GI50 values of above 10 mM for the Capan1,
Panc10.05 and AsPc1 lines, and a GI50 of 1.54 mM for the L3.3
line (Figure 4A).
In addition, we tested response of a larger panel of K-RAS
mutant pancreatic cell lines to the PI3K inhibitor GDC0941 and
to the MEK inhibitor AZD6244 [33-35]. GI50 values of a few
pancreatic lines were close to the GI50 = 80 nM observed for the
sensitive line MCF7, however, none of the pancreatic lines was as
sensitive as the line MCF7 (Figure 4B). In contrast, 50% of lines
tested for sensitivity to the MEK inhibitor AZD6244 showed GI50
values comparable to the values obtained for the sensitive line A-
375 (GI50 = 34 nM) (Figure 4C). Thus, a substantial number of K-
RAS mutant pancreatic lines were sensitive to MEK inhibition
in vitro.
Pancreatic Models Show Higher Sensitivity to MEK than
to PI3K Inhibition in vivo
Having shown K-RAS dependence of the xenograft models, the
question as to the role of the downstream pathways MAPK and
PI3K in tumor maintenance arises. Selected nude mouse
xenograft models were tested for antitumor response to the
PI3K inhibitor GDC0941 or the MEK inhibitor AZD6244. Rat1-
myr-p110a tumors were used as control for PI3K dependence,
whereas A-375 tumors were our control for MEK dependence. As
expected, Rat1-myr-p110a tumors showed slight tumor regression
upon treatment at the reported efficacious dose level of the PI3K
inhibitor GDC0941 (T/C=23%), but tumors did not regress
upon treatment with the MEK inhibitor AZD6244 (T/C=29%)
[36]. In contrast, A-375 tumors, harboring an activating B-RAF
mutation, responded strongly to AZD6244 (T/C=228%), but
did not show significant sensitivity to GDC0941 (T/C=66%)
(Figure 5A). We then tested the response of three pancreatic
models (MIA PaCa-2, L3.3 and Panc 10.05). The MIA PaCa-2
model was included because the cell line showed the highest
sensitivity to MEK inhibition amongst the pancreatic lines tested in
vitro (Figure 4C). Interestingly, all three models displayed
statistically significant tumor regression upon treatment with
AZD6244 (T/C(MIA PaCa-2) =214%, T/C(L3.3) =212%, T/
C(Panc 10.05) =224%), while modest growth inhibition but no
tumor regression was observed in response to GDC0941 treatment
(T/C(MIA PaCa-2) = 69%, T/C(L3.3) = 18%, T/C(Panc
10.05) = 44%) (Figure 5B). It has to be noted that in vivo efficacy
correlated poorly with in vitro sensitivity, and so in vitro data might
not be useful for predicting the in vivo response of pancreatic
cancer models (Figure 4B and C). Drug plasma levels were
comparable between the Rat1-myr-p110a and the Panc 10.05
models after a single treatment, indicating sufficient absorption of
either compound (Figure 6A and B). Moreover, respective targets
were found to be inhibited in both models, with very low pERK
and pAKT levels following drug exposure. As expected, basal
pAKT levels were low in the pancreatic model Panc 10.05, and so
inhibition of pAKT seemed less pronounced compared to the high
pAKT-expressing model Rat1-myr-p110a (Figure 6C and D). In
conclusion, all three pancreatic models tested in vivo showed higher
dependence on MAPK than on PI3K signaling, indicating that it is
the MAPK pathway playing the major role in tumor maintenance.
Combining MEK and PI3K Inhibition in vivo is Superior to
Single Agent Treatment
A number of studies have reported synergy for combined use of
MEK and PI3K inhibitors in K-RAS mutant breast, lung and
colorectal tumor models [14–15,24–26]. PI3K inhibition had
limited effect on tumor growth in the pancreatic models tested,
however, PI3K has well described functions in the tumor stroma of
pancreatic cancers, and therefore combined application of a PI3K
and a MEK inhibitor might prove beneficial by targeting both
tumor cells as well as stromal cells [20]. As expected, treatment of
nude mice bearing MIA-PaCa-2 tumors with the PI3K inhibitor
GDC0941 alone resulted in limited tumor growth inhibition (T/
C=41%). Treatment with the MEK inhibitor AZD6244 alone
was done at a lower dose of 5 mg/kg and led to a similar tumor
growth inhibition with a T/C of 33%. Notably, combining
GDC0941 and AZD6244 showed synergistic tumor regression
with a T/C of 220% (Figure 7A). pAKT and pERK were found
inhibited upon exposure to a single dose of respective compound,
as well as upon combination treatment (Figure 7C). To test the
effect of the MEK/PI3K combination on a second K-RAS mutant
pancreatic xenograft model, nude mice bearing Panc 10.05 tumors
were treated with AZD6244, GDC0941 or the combination of
both. Treatment with either inhibitor alone resulted in tumor
growth inhibition with a T/C of 47% upon AZD6244 application
and a T/C of 12% upon GDC0944 application. As observed for
the MIA PaCa-2 model, combination of AZD6244 and GDC0941
led to tumor regression with a T/C of 233% (Figure S3). Thus,
combining MEK and PI3K inhibitors is superior to single agent
treatment in two in vivo models of the pancreatic lineage.
Discussion
Patients with advanced pancreatic ductal adenocarcinoma
(PDAC) are commonly treated with the chemotherapeutic
gemcitabine. As 5 year survival rates are very low (,5%), new
therapies are clearly needed [37]. Genetic mouse models have
helped to understand the crucial role of activating K-RAS
mutations in the onset and maintenance of pancreatic cancer
[3–6]. To investigate K-RAS dependent tumor maintenance of
human cell lines, we generated an inducible K-RAS shRNA knock
down system which allowed us to ablate K-RAS expression in
Figure 2. K-RAS knock down impairs tumor growth of pancreatic models in vivo. (A) For each xenograft model indicated, tumors were
grown subcutaneously in female nude mice and groups of at least 4 mice each were formed once tumors had reached a size of 200–300 mm3. The
first group was given normal drinking water, whereas the second was given drinking water containing 2 mg/ml doxycycline and 10% sucrose. Mice
were sacrificed after one week of treatment (after 18 days in case of the K-RAS wild type model), and tumors were analyzed by qPCR for K-RAS. K-RAS
levels were normalized to ribosomal protein s18. Obtained p-values were as follows: Capan-1 shNT: p = 0.35, Capan-1 sh236: p = 0.011, Panc 10.05
sh236: p = 0.009, AsPC-1 sh236: p = 0.002, L3.3 sh236: p = 0.004, NCI-H1437 sh236: p = 0.007. (B/C) As in (A), except that mice were randomized to
groups of at least 6 mice each, with the exception of the Panc 10.05 model, where the group size was n= 4. Treatment was started once tumors had
reached a size of 100 mm3, tumor size was followed over time, and mice were sacrificed once tumors of the control group reached a size of 1000
mm3 at most. Statistically significant differences of tumor volumes between groups (*) as well as the area under the curve (AUC/mm3 x treatment
days) are indicated. Obtained p-values for AUC at the end of the study were as follows: Capan-1 shNT: p = 0.57, Capan-1 sh236: p = 0.04, Panc 10.05
sh236: p = 0.01, AsPC-1 sh236: p = 0.01, L3.3 sh236: p = 0.0003, NCI-H1437: p = 0.22. The PANC-1 cells could not be grown in vivo, and for this reason
this model was only examined in vitro.
doi:10.1371/journal.pone.0044146.g002
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established tumors. In all four pancreatic xenograft models
studied, we observed impaired tumor growth upon K-RAS knock
down. Thus, as in the genetic mouse model, K-RAS is required for
tumor maintenance of human xenografts of the pancreatic lineage
in vivo.
No specific inhibitors targeting K-RAS have been developed to
date, and so the identification of the key effectors mediating tumor
maintenance might lead to alternative therapeutic opportunities.
Such downstream targeting has the caveat that the oncogene itself
stays active and inhibition might therefore not be complete. As all
attempts to target K-RAS have failed so far, targeting downstram
signaling pathway seems a promising alternative at present [7].
Notably, all three pancreatic xenograft models tested in vivo
showed regression upon MEK, but not upon PI3K inhibition.
This indicates higher dependence of established pancreatic tumors
on MAPK than on PI3K signaling. Similar results have been
described for K-RAS induced lung tumors, with MEK but not
PI3K inhibition leading to tumor regression [14–15]. Therefore,
MAPK signaling might - in addition to its prominent role in the
lung - also play a major role in the maintenance of pancreatic
tumors. Future studies will be needed to understand if this might
be a more general phenomenon across K-RAS mutant tumors.
At present, the mechanism explaining the stronger response to
MEK than to PI3K inhibition in the pancreatic xenografts
examined is not known. We showed K-RAS to signal via MAPK,
and so it is tempting to speculate that sensitivity to MEK inhibitors
is linked to pathway activity in these models. A few in vivo models
of K-RAS mutant pancreatic cancers have been described to be
sensitive to MEK inhibition, whereas K-RAS mutations have been
shown to be predictive of resistance to treatment with PI3K
inhibitors in several tumor types [17–19]. The mechanism of
insensitivity to PI3K inhibition was not further elucidated in these
publications, and future studies will be required to gain such
insight. None of these studies have directly compared response to
MEK versus PI3K inhibition.
Inhibition of PI3K actually resulted in tumor growth inhibition
in the model L3.3, though to a less dramatic extent than upon
MEK inhibition. As was the case for all pancreatic models tested,
the L3.3 model showed low pAKT levels and independence of
AKT signaling. PI3K signaling appears to depend upon PDK1
rather than AKT in several breast cancer cell lines harboring the
H1047R mutation in PIK3CA, and thus it remains to be seen if
a similar mechanism exists in the L3.3 model [38]. Moreover, the
L3.3 line is wild type for p53, whereas all other lines tested in vivo
harbor mutations in the gene. It would be interesting to investigate
if there is a link between p53 status and response to PI3K
inhibition.
A number of PI3K and MEK inhibitors are currently being
developed and tested in clinical studies [39–40]. PI3K inhibitors
have been tested in phase I studies in patients with solid tumors
with promising outcomes [41]. However, no phase II data is
available yet, and thus future studies need to be awaited to
conclude upon the effectiveness of such inhibitors. AZD6244 has
been tested in a phase II study in patients with advanced
pancreatic cancer, with the outcome of no statistically significant
difference in overall survival between AZD6244 and standard of
care [42]. This result is in disagreement to our data, showing
regression of K-RAS mutant pancreatic tumors in xenograft
models. It must be noted that the clinical trial was performed as
second-line treatment on a patient population with advanced
pancreatic cancer who have failed first-line gemcitabine therapy. It
is possible that MEK inhibition as first-line treatment for
pancreatic cancer might prove to be more effective. In vitro,
MEK inhibition was not effective in a gemcitabine resistant
pancreatic line established by exposure to the chemotherapeutic
[43]. Furthermore, hypoxia has been used to induce gemcitabine
resistance in pancreatic cell lines, and such cells proved to be
unresponsive to MEK inhibition. Interestingly, the same cell line
was sensitive to gemcitabine as well as to MEK inhibition under
normoxic conditions [44]. These data indicate that MEK
inhibitors might indeed not be effective on gemcitabine resistant
cells. Such gemcitabine resistance could be reversed in a genetic
mouse model of pancreatic cancer by inhibition of the hedgehog
pathway, which mediated remodeling of the tumor stroma and
thus facilitated uptake of gemcitabine into the tumor [45]. Hence
one could speculate that a PI3K inhibitor as well as other
modalities might have similar effects on the stromal compartment,
leading to increased drug penetration of the tumor and in this way
to increased gemcitabine sensitivity [20,46–49].
Moreover, target inhibition in the tumors was not determined in
this phase II study, and it is possible that pERK levels were not
sufficiently decreased to show efficacy. Tumors generally show
vascular abnormalities, with dilated, irregular vessels which are
poorly functional [50]. Pancreatic tumors are known to be
hypoperfused and therefore show limited uptake of drugs [51].
This phenomenon is less prevalent in the case of transplanted
tumors like the xenograft models used in our study [45]. Thus, it is
possible that MEK inhibition had limited success in above
mentioned trial because the drug could not sufficiently enter the
tumors.
Targeting the tumor stroma in a genetic mouse model of
pancreatic cancer led to changes in the tumor vasculature which
allowed increased uptake of the drug into the tumor, resulting in
improved efficacy [45]. A number of publications have shown that
GDC0941 as well as other PI3K inhibitors lead to remodeling of
the tumor vasculature, resulting in increased drug uptake [46–49].
Combined application of PI3K inhibitors might therefore be
generally beneficial in enhancing the delivery of drugs into the
tumor. When we treated nude mice bearing MiaPaCa-2 tumors -
which showed limited sensitivity to PI3K inhibition in vivo - with
a combination of a MEK and a PI3K inhibitor, we observed an
effect superior to MEK inhibition alone. A second xenograft
model, mice bearing Panc 10.05 tumors, responded similarly and
showed benefit of combined administration of a MEK and a PI3K
inhibitor. This indicates that K-RAS mutant pancreatic xenografts
might generally show superior response upon MEK/PI3K in-
hibitor combination treatment. The mechanism of this synergy has
not been investigated, however, it is possible that the combination
is beneficial by targeting both tumor cells and tumor stroma.
Future studies are clearly needed to support this hypothesis, and to
investigate if PI3K inhibition aids the uptake of the MEK inhibitor
into the tumor.
Combination treatment of K-RAS mutant breast, lung and
colorectal tumors with a MEK and a PI3K inhibitor has been
Figure 3. K-RAS knock down results in decreased pERK levels in vivo. For each xenograft model indicated, tumors were grown
subcutaneously in female nude mice and groups of at least 4 mice each were formed once tumors had reached a size of 200–300 mm3. The first
group was given normal drinking water (-dox), whereas the second was given drinking water containing 2 mg/ml doxycycline and 10% sucrose
(+dox). After one week of treatment, mice were sacrificed and the tumors were removed and processed for immunohistochemistry for either pERK
(Thr202/Tyr204) (A), or pAKT (Ser473) (B). The T47D model was used as an AKT dependent control model with physiological pAKT levels.
doi:10.1371/journal.pone.0044146.g003
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Figure 4. K-RAS mutant pancreatic lines are independent of AKT in vitro. (A). Indicated cell lines were treated for 72 h with the AKT inhibitor
MK2206, and effects on proliferation were determined by calculation of respective GI50 values. (B/C). As in (A), except that indicated cell lines were
treated for 62 h with either the PI3K inhibitor GDC0941 (B) or with the MEK inhibitor AZD6244 (C), and effects on proliferation were determined by
calculation of respective GI50 values. MCF7 cells were used as control for cells sensitive to GDC0941 and insensitive to AZD6244 and A375 cells were
used as control for cells sensitive to AZD6244 and insensitive to GDC0941.
doi:10.1371/journal.pone.0044146.g004
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shown to be superior to single agent treatment. Frequently, the
combination led to enhanced induction of apoptosis [14–15,24–
26]. Moreover, resistance to MEK inhibition was found to be
mediated by activation of PI3K signaling in several lineages, and
inhibition of both pathways showed synergistic effects [22–23]. It
remains to be seen whether a similar resistance mechanism takes
place in pancreatic tumors; the existence of which would provide
Figure 5. K-RAS mutant pancreatic models show stronger response to MEK than to PI3K inhibition in vivo. (A/B). Indicated tumor-
bearing mice were treated either with GDC0941 100 mg/kg p.o. once a day, or with AZD6244 50 mg/kg p.o. twice a day, or with vehicle control, with
at least 5 mice per group. Tumor volumes were measured twice a week for the indicated period of time, and antitumor activity was plotted and
quantified.
doi:10.1371/journal.pone.0044146.g005
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better understanding of the synergy seen with the PI3K and MEK
inhibitor combination.
Our data on combining MEK and PI3K inhibition in
pancreatic xenograft models supports use of this combination for
future clinical trials. Indeed, such combination trials are currently
being prepared, and the results of these are eagerly awaited with
the hope that such treatment will result in improved responses in
the clinic.
Materials and Methods
Ethics Statement
All animal experiments were fully approved by the Kantonales
Veterina¨ramt Basel-Stadt under license #1769 and were con-
ducted in accordance with the Eidgeno¨ssisches Tierschutzgesetz
and the Eidgeno¨ssische Tierschutzverordnung.
Chemical Compounds
GDC0941, AZD6244 and MK2206 were obtained from Selleck
Chemicals, Boston, USA.
Cell Lines and Cell Culture
Cell lines were purchased from the American Type Cell
Collection (Manassas, USA). All lines were cultured at 37uC, 5%
CO2 and 80% relative humidity in DMEM high glucose (Gibco,
Carlsbad, USA) complemented with 10% fetal bovine serum (20%
in case of the cell line Capan1), 2 mM glutamine and 1%
penicillin-streptomycin.
Cell Lysate Preparation and Immunoblotting
Cells were washed with cold PBS and lysed in 1% NP40 lysis
buffer. Lysates were centrifuged for 10 min at 13000 rpm to remove
cellular debris, and the protein concentration was determined using
the Bradford test. Tumor lysates were prepared by homogenizing
the tumors, resuspending the powder in 1% NP40 lysis buffer
followed by a centrifugation step for 10 min at 13000 rpm and
determination of the protein concentration. Western blotting was
done on PVDF membranes using PBS/Tween (0.1%) milk and the
following antibodies: AKT (Epitomics, Burlingame,USA;#1085-1,
1:1000), pAKT (Ser473; CST, Canvers, USA; #9271, 1:1000),
ERK (CST#9102, 1:1000), pERK (Thr202/Tyr204; CST#9101,
1:1000), andK-RAS (Santa Cruz Biotechnology, Santa Cruz, USA;
#sc230, 1:200). HRP labeled secondary antibodies were detected
using ECL (Amersham Biosciences, Little Chalfont, UK) and
autoradiography.
Lentivirus Production and Infection
HEK 293FT cells were transfected with DNA-Lipofectamine
complexes (Invitrogen, Carlsbad, USA) containing pVPRD8.71,
pVSVG and LKO-Tet-ON vector [52]. The next day, 1 mM
sodium pyruvate and 10 mM sodium butyrate were added to the
medium for 8 h. Virus was harvested 24 h later, filtered and
titrated in MIA PaCa-2 cells.
Cells were spinfected at 2000 rpm for 2 h in medium containing
Tet-free FCS and 8 mg/ml polybrene at an MOI= 1. Medium
was changed 8–16 h post-infection, and puromycin selection was
started and maintained after 30 h of recovery at 1 mg/ml. Target
sequences of shRNAs: K-RAS sh236: 59 GATACAGCTAATT-
CAGAATC 39; K-RAS sh562: 59 AGGCTCAGGACTTAG-
CAAGA 39; shNT: 59 GGATAATGGTGATTGAGATGG 39.
Proliferation Assay
Cells were plated in 96 well plates with 6 replicates per
condition. The next day, doxycycline was added at 200 ng/ml and
changed every 3 days. Cells were fixed in glutaraldehyde at
indicated days, stained in methylene blue, washed, the dye was
eluted in 3% HCl, and the plates were read at OD=650 nm.
Statistics were calculated by performing a t-test; p-values ,0.05
Figure 6. GDC0941 and AZD6244 in vivo treatment inhibits pAKT and pERK respectively. Indicated tumor-bearing mice were treated with
a single dose of either GDC0941 100 mg/kg p.o., or AZD6244 50 mg/kg p.o., or with vehicle control. Animals were sacrificed 1 h after treatment,
plasma samples were collected, analyzed and quantified by mass spectrometry for GDC0941 (A) or AZD6244 (B). Tumors were excised and analyzed
by Western Blot for total AKT, pAKT (Ser473), total ERK or pERK (Thr202/Tyr204) for the model Rat1-myr-p110a (C) or the model Panc 10.05 (D).
doi:10.1371/journal.pone.0044146.g006
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were considered statistically significant. In cases where the equal
variance or the normality test failed, a Whitney- Mann test was
performed.
For determination of GI50 values, cell lines were plated in
96 well plates. The next day, cells were treated with the AKT
inhibitor MK2206 at compound concentrations ranging from
10 mM to 1 nM (from 20 mM to 1 nM for treatment with the
PI3K inhibitor GDC0941 or the MEK inhibitor AZD6244). After
an incubation of 72 h, cells were fixed and stained as described
above. Conditions were done in duplicate, and at least 2 in-
dependent experiments were performed for each cell line.
qPCR
RNA was isolated from frozen tumor powder and 2 mg RNA
were reverse transcribed (Applied Biosystems, Foster City, USA).
qPCR reactions were performed with 40 ng of transcribed RNA
(qPCR core kit for SYBR Green, Eurogentec, Liege, Belgium)
using following primers designed to be human-specific and to cross
an exon-intron boundary: K-RAS: forward 59 ctaaatcatttgaaga-
tattcacc 39; reverse 59ctgatgtttcaataaaaggaattc 39. qPCR of RPS18
was done using the TaqMan probe 4319413E (Applied Biosys-
tems). Statistics were calculated by performing a t-test; p-values
,0.05 were considered statistically significant. In cases where the
Figure 7. Combining MEK and PI3K inhibition in vivo is superior to single agent treatment. (A). Indicated tumor-bearing mice were
treated either with GDC0941 100 mg/kg p.o. once a day, or with AZD6244 5 mg/kg p.o. once a day, or with the combination of both, or with vehicle
control, with 8 mice per group. Tumor volumes were measured twice a week, for the indicated period of time, and antitumor activity was plotted and
quantified. (B). Indicated tumor-bearing mice were treated with a single dose of either GDC0941 100 mg/kg p.o. or of AZD6244 5 mg/kg p.o., with
the combination of both or with vehicle control. Animals were sacrificed 3 h after treatment, tumors were excised and analyzed by Western Blot for
total AKT, pAKT (Ser473), total ERK or pERK (Thr202/Tyr204).
doi:10.1371/journal.pone.0044146.g007
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equal variance or the normality test failed, a Whitney-Mann test
was performed.
Immunohistochemistry
Tumors were fixed after dissection in 10% neutral buffered
formalin for 24 h at RT, rinsed in PBS, processed for dehydration,
cleared and paraffinized. After embedding in paraffin, 3 mm
sections were prepared. IHC staining was done on a Discovery XT
platform (Ventana Medical Systems, Tucson, USA) using CC ultra
mild epitope recovery conditions for pERK and CC ultra
extended for pAKT. The detection system used was OmniMap
DAB anti–Rabbit (HRP) detection kit (Ventana Medical Systems).
Slides were hematoxylin counterstained and antibodies used were
pAKT (Ser473; CST #4060, 1:25) and pERK (Thr202/Tyr204;
CST #4370, 1:400).
Xenograft Studies
For K-RAS knock down studies in vivo, female Harlan nude
mice (Harlan Inc., Indianapolis, USA) were injected s.c. with 5
million cells in 100 ml HBSS, the Panc 10.05 cells were injected
with 50% Matrigel. At a tumor volume of around 100 mm3 (200–
300 mm3 for one-week treatments), mice were randomized to one
of two groups and treated in the presence or absence of
doxycycline. Doxycycline treatment was done by adding 2 mg/
ml doxycycline in 10% sucrose in the drinking water. Tumor
volumes were followed over time and are shown as mean volume
+/2 standard error of the mean. At the end of each study, tumors
were excised and processed for IHC or qPCR. Tumor volumes
were determined by using calipers for measurement of longest
(considered as length) and shortest (considered as diameter)
dimensions of each tumor and according to the formula V= (p *
L * (D2))/6, with L= tumor length and D= tumor diameter.
Statistics were calculated by performing a t-test. p-values ,0.05
were considered statistically significant.
For inhibitor studies of pancreatic models in vivo, female Harlan
nude mice were injected s.c. with 10 million cells in 100 ml HBSS,
the MIA PaCa-2 and the Panc 10.05 cells were injected with 50%
Matrigel. At a tumor volume of around 600 mm3, tumor pieces
were transplanted s.c. Once these tumors were established to a size
of around 100 mm3, mice were randomized to one of three
groups. The Rat1-myr-p110a and the A-375 model were
established by injecting 5 million cells s.c. GDC0941 and
AZD6244 (free base) were formulated in NMP/PEG300 (10/90,
V/V). GDC0941 was given at 100 mg/kg once a day p.o.,
AZD6244 at 50 mg/kg twice a day p.o. and NMP-PEG was given
twice a day p.o. Tumor volumes were followed over time and are
shown as mean volume +/2 standard error of the mean. When
required, tumors were excised at the end of the study and
processed for Western blot, and blood was taken for PK studies.
Antitumor activity is expressed as T/C% (mean increase of tumor
volumes of treated animals divided by the mean increase of tumor
volumes of control animals multiplied by 100).
For combination studies, female Harlan nude mice were
injected s.c. with 5 million MIA PaCa-2 cells in 100 ml HBSS
containing 50% Matrigel. Once tumors were established to a size
of around 150 mm3, mice were randomized to one of four groups.
GDC0941 and AZD6244 (free base) were formulated in NMP/
PEG300 (10/90, V/V). GDC0941 was given at 100 mg/kg once
a day p.o., AZD6244 at 5 mg/kg once a day p.o. and NMP-PEG
was given once a day p.o. The combination was given at 100 mg/
kg GDC0941 once a day p.o., and 5 mg/kg AZD6244 once a day
p.o. Tumor volumes were followed over time and are shown as
mean volume +/2 standard error of the mean. Synergy was
determined using the Clarke method [53].
Statistical analysis was done by a one way ANOVA Tukey test;
p-values ,0.05 were considered statistically significant. In case the
normality or the equal variance test failed during this analysis, log
tranformed data was used for the one way ANOVA Tukey test. In
case of normality or equal variance tests failing for both
untransformed and log transformed data, an ANOVA on ranks
test was performed.
Determination of Compound Plasma Concentrations
Mouse plasma was chromatographically separated by HPLC
(Agilent, Santa Clara, USA) on a RESECTTM Ultra Phenyl
reverse-phase column. Compound concentrations were deter-
mined using a Quattro MicroTM mass spectrometer (Waters,
Milford, USA) by comparison to a compound standard.
Supporting Information
Figure S1 The L3.3 sh562 cell line shows increased
doubling times. Indicated L3.3 pools were either exposed to
200 ng/ml of doxycycline (dox) or not exposed to doxycycline (no
dox) for 7 days, and relative cell numbers were quantified. The
doubling time was subsequently calculated using the following
formula: doubling time= t*((LN(2))/(LN(OD650-t2/OD650-t1)),
with t = incubation time, OD650-t2 =OD650 after 7 days of
growth, OD650-t1 =OD650 at time of doxycycline addition.
(TIF)
Figure S2 Proliferation of the K-RAS wt line NCI-H1437
is not affected upon K-RAS knock down. (A) NCI-H1437
cell pools (NT: non-targeting shRNA; 236: shRNA targeting K-
RAS) were either treated for 7 days with 200 ng/ml of doxycycline
(dox) or left untreated (no dox), followed by preparation of cell
lysates. Corresponding cell extracts were then analyzed for K-RAS
and total AKT levels by Western Blot. (B) As in (A), except that
cells were fixed on day 1 and day 7, followed by determination of
proliferation. Each cell line was tested in at least two independent
experiments and untreated samples were set to 100% of growth.
(TIF)
Figure S3 Combined application of a PI3K and a MEK
inhibitor is superior to single agent treatment in the
model Panc 10.05. Indicated tumor-bearing mice were treated
either with GDC0941 100 mg/kg p.o. once a day, or with
AZD6244 5 mg/kg p.o. once a day, or with the combination of
both, or with vehicle control, with 6 mice per group. Tumor
volumes were measured twice a week, for the indicated period of
time, and antitumor activity was plotted and quantified.
(TIF)
Table S1 Mutational status of pancreatic cell lines
used. The mutational status of K-RAS, TP53, CDKN2A and
SMAD4 of the panel of pancreatic cell lines was collected from the
Cosmic database or from Oncomap. In cases where K-RAS
mutation status was not available, sequencing was performed
internally (NVS). Cell lines in bold were tested in vivo.
(PPT)
Table S2 Antitumor activities obtained in pancreatic
models upon K-RAS knock down. Data shown in Figure 2B
and 2C was analyzed by calculating the doubling time of the
tumors, T/C (treatment/control) on day 18 (minimum treatment
period), T/C on the last day of each study, and D tumor volume
between the start and end of the study, as well as the area under
the curve (AUC). Statistics were calculated by performing a t-test.
No t-test calculation was possible for the doubling time of the
model Capan-1 K-RAS sh236, as there was no tumor growth for 2
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tumors in the doxycycline treated group resulting in infinite
doubling times. An outlier determined by the Grubb’s test
amongst the doubling times calculated for the model AsPC-1 K-
RAS sh236 was not considered in the analysis.
(PPT)
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